Caribou Halts Lead CAR-T Programs, CFO to Exit as Strategic Review Begins
CRBU is trading near its 52-week low of $1.13 (38% below the low).
Summary
Caribou is discontinuing its two lead allogeneic CAR-T programs, vispa-cel and CB-011, and cutting most of its workforce as it explores strategic alternatives including a possible merger or sale. The company expects $15M to $19M in restructuring costs, mostly in Q4 2026, and the workforce reduction should be largely complete by then. CFO Sriram Ryali has agreed to step down once a binding definitive agreement for a strategic alternative is executed. This follows the 8-K filed earlier today and adds new details on the CFO departure, restructuring expense range, and timeline. The stock fell 36% after hours to $0.73, near its 52-week low.
At the time of this announcement, CRBU was trading at $0.71 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $121.7M. The 52-week trading range was $1.13 to $3.54. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.